Possible Biomarker for immune checkpoint inhibitor

被引：0
|
作者：
Takeuchi, Yoshiko [1 ,2 ]
Nishikawa, Hiroyoshi [1 ,3 ,4 ]
机构：
[1] Natl Canc Ctr, Div Canc Immunol, EPOC, Tokyo, Japan
[2] Osaka Univ, Dept Resp Med Allergy & Rheumat Dis, Grad Sch Med, Suita, Osaka, Japan
[3] Natl Canc Ctr, Res Inst, Grp Frontier Sci, Div Canc Immunol, Tokyo, Japan
[4] Nagoya Univ, Grad Sch Med, Immunol Cellular Immunol, Nagoya, Aichi, Japan
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ISY8-3
引用
收藏
页码：20 / 20
页数：1
相关论文
共 50 条
  • [31] POLE and POLD1 Variant Detection: Potential Immune-Checkpoint Inhibitor Biomarker
    Besharati, Sepideh
    Fazlollahi, Ladan
    Remotti, Helen
    MODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 491 - 491
  • [32] Proceedings From the ASCO/College of American Pathologists Immune Checkpoint Inhibitor Predictive Biomarker Summit
    Hayes, Daniel F.
    Herbst, Roy S.
    Myles, Jonathan L.
    Topalian, Suzanne L.
    Yohe, Sophia L.
    Aronson, Naomi
    Bellizzi, Andrew M.
    Roy, Upal Basu
    Bradshaw, Georganne
    Edwards, Robin H.
    El-Gabry, Ehab A.
    Elvin, Julia
    Gajewski, Thomas F.
    McShane, Lisa M.
    Oberley, Matthew
    Philip, Reena
    Rimm, David L.
    Rosenbaum, Jason N.
    Rubin, Eric H.
    Schlager, Lisa
    Sherwood, Shimere W.
    Stewart, Mark
    Taube, Janis M.
    Thurin, Magdalena
    Vasalos, Patricia
    Laser, Jordan
    JCO PRECISION ONCOLOGY, 2022, 6
  • [33] POLE and POLD1 Variant Detection: Potential Immune-Checkpoint Inhibitor Biomarker
    Besharati, Sepideh
    Fazlollahi, Ladan
    Remotti, Helen
    LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 491 - 491
  • [34] Mutation in CDC42 Gene Set as a Response Biomarker for Immune Checkpoint Inhibitor Therapy
    Wang, Kun
    Zhang, Yingying
    Su, Zhaoming
    Wang, Bei
    Zhou, Yuanyang
    Tong, Xiaochu
    Xie, Chengying
    Luo, Xiaomin
    Zhang, Sulin
    Zheng, Mingyue
    CANCER MEDICINE, 2025, 14 (01):
  • [35] Monocyte chemoattractant protein 1 as a potential biomarker for immune checkpoint inhibitor-associated neurotoxicity
    Moehn, Nora
    Mahjoub, Susann
    Duzzi, Laura
    Narten, Emily
    Grote-Levi, Lea
    Koerner, Gudrun
    Seeliger, Tabea
    Beutel, Gernot
    Bollmann, Benjamin-Alexander
    Wirth, Thomas
    Huss, Andre
    Tumani, Hayrettin
    Grimmelmann, Imke
    Gutzmer, Ralf
    Ivanyi, Philipp
    Skripuletz, Thomas
    CANCER MEDICINE, 2023, 12 (08): : 9373 - 9383
  • [36] ER expression as a predictive biomarker for Immune Checkpoint Inhibitor Therapy in ER positive breast cancer
    Arima, Jun
    Taniguchi, Kohei
    Inomata, Yosuke
    Hagihara, Seita
    Suzuki, Shigenori
    Lee, Sangwoong
    CANCER SCIENCE, 2025, 116 : 1149 - 1149
  • [37] POLE and POLD1 Variant Detection: Potential Immune-Checkpoint Inhibitor Biomarker
    Besharati, Sepideh
    Fazlollahi, Ladan
    Remotti, Helen
    MODERN PATHOLOGY, 2022, 35 : 491 - 491
  • [38] Retrospective analysis of digital biomarker predictability of immune checkpoint inhibitor therapy outcomes in patients with NSCLC
    Abousaud, Marin
    Frame, David
    Harvey, R. Donald
    Kaddoura, Layan
    Ekpenyong, Asari
    Abousaud, Aseala
    Steuer, Conor Ernst
    Derstine, Brian
    Wang, Nicholas C.
    Mackler, Emily R.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [39] Radiology in the immune checkpoint inhibitor era
    Park, Benjamin C.
    Johnson, Douglas B.
    Lewandowski, Robert J.
    CLINICAL IMAGING, 2024, 107
  • [40] Chronic immune checkpoint inhibitor pneumonitis
    Naidoo, Jarushka
    Cottrell, Tricia R.
    Lipson, Evan J.
    Forde, Patrick M.
    Illei, Peter B.
    Yarmus, Lonny B.
    Voong, K. Ranh
    Feller-Kopman, David
    Lee, Hans
    Riemer, Joanne
    Wang, Daphne
    Taube, Janis M.
    Brahmer, Julie R.
    Lin, Cheng Ting
    Danoff, Sonye K.
    D'Alessio, Franco R.
    Suresh, Karthik
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
12345